D69.51 Posttransfusion purpura

Name of the Condition

• Posttransfusion purpura

Summary

Posttransfusion purpura is a rare immune-mediated condition characterized by sudden thrombocytopenia (low platelet count) following blood transfusion. It typically occurs in individuals with a history of prior sensitization to platelet antigens, leading to platelet destruction and potential bleeding complications.

Causes

Posttransfusion purpura results from an immune response to foreign platelet antigens introduced during transfusion. The body produces antibodies against these antigens, which cross-react with the patient’s own platelets, causing their destruction. This reaction is often triggered by platelet-specific antigens, such as HPA-1a, and may involve prior exposure to platelets through pregnancy, transfusion, or organ transplantation.

Risk Factors

• Prior exposure to platelet antigens (e.g., previous transfusions, pregnancy, or organ transplants)
• Presence of specific platelet antigen antibodies (e.g., anti-HPA-1a)
• Female gender (due to higher likelihood of sensitization during pregnancy)
• History of autoimmune disorders

Symptoms

• Sudden onset of bruising or purpura (purple discoloration of the skin)
• Bleeding from mucous membranes (e.g., nose, gums)
• Prolonged bleeding from minor injuries
• Fatigue or weakness (if severe thrombocytopenia develops)
• In rare cases, life-threatening hemorrhage

Diagnosis

Diagnosis involves clinical evaluation of symptoms following transfusion, laboratory testing to confirm thrombocytopenia, and identification of platelet-specific antibodies. A history of prior sensitization and exclusion of other causes of low platelet count are critical. Additional tests may include platelet antigen typing and antibody screening.

Treatment Options

• Supportive care with platelet transfusions (if bleeding is severe)
• Intravenous immunoglobulin (IVIG) to reduce antibody-mediated platelet destruction
• Corticosteroids to suppress the immune response
• Plasmapheresis in refractory cases
• Monitoring platelet counts until recovery

Prognosis and Follow-Up

Most patients recover within 1–2 weeks with appropriate treatment, though severe cases may require prolonged monitoring. Follow-up includes regular platelet count checks and evaluation for bleeding complications. Long-term prognosis is generally favorable, but recurrence is possible with future transfusions.

Complications

• Severe bleeding (e.g., intracranial hemorrhage)
• Prolonged thrombocytopenia
• Transfusion reactions
• Delayed recovery due to underlying immune sensitization

Lifestyle & Prevention

• Avoid unnecessary blood transfusions when possible
• Use leukoreduced or antigen-matched blood products in sensitized individuals
• Inform healthcare providers of prior transfusion or pregnancy history
• Monitor for signs of bleeding and seek prompt care if symptoms occur

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Sudden bruising or purpura after transfusion
• Uncontrolled bleeding from minor injuries
• Severe fatigue or dizziness
• Signs of internal bleeding (e.g., blood in urine, stools, or vomit)

Tips for Medical Coders

Document the timing of symptom onset relative to transfusion, as posttransfusion purpura typically occurs within days to weeks after exposure. Include details of prior sensitization (e.g., pregnancy, transfusion history) and confirmatory lab results (e.g., platelet counts, antibody testing) to support the diagnosis. Ensure the code D69.51 is used when the condition is specifically attributed to posttransfusion causes.